SBFMW · Insider Trading
Sunshine Biopharma Inc. warrant
Every open-market purchase and sale reported by SBFMW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-14 | David Natan | Director | A | +100,000 | — |
| 2024-03-05 | Steve N. Slilaty | Chief Executive Officer | Buy | +100,000 | +$10.00K |
| 2024-02-12 | Steve N. Slilaty | Chief Executive Officer | Buy | +20,000 | +$2.00K |
| 2022-12-02 | Camille Sebaaly | CFO/Secretary | Buy | +30,000 | +$22.91K |
| 2022-06-06 | Camille Sebaaly | CFO/Secretary | Buy | +25,000 | +$30.50K |
| 2022-02-22 | Steve N. Slilaty | Chief Executive Officer | D | −990,000 | −$99.00K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David Natan | Director | 100,000 | $2.50K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SBFMW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.